AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Inclusion Criteria: 1、BCMA positive accompanied by refractory/relapsed and resistance; 2、Patients with the tumor load is high and cannot be transplanted directly, before transplantation. Reduce the load through CAR-T treatment to prepare for transplantation; 3、Patient relapses after transplantation,donor lymphocyte infusion Invalid. The donor cells in the recipient body can be used or the donor cells can be collected directly.Prepare CAR-T to prevent recurrence and induce relapsing; 4、Repeated MRD (+) refractory drug resistant cases; 5、Male or female, 30-75 years old; 6、Anticipated survival time more than 12 weeks 7、Transplant subjects, regardless of their previous treatment, are eligible for inclusion after relapse； 8、Patients had a negative urine pregnancy test before the start of administration and agreed to take effective contraceptive measures during the test period until the last follow-up; 9、Those who voluntarily participate in the trial and sign the informed consent form Exclusion Criteria: 1、Patients with the history of epilepsy or other CNS disease； 2、Patients with prolonged QT interval time or severe heart disease； 3、Pregnant or breastfeeding; 4、Active infection with no cure; 5、Patients with active hepatitis B or C infection; 6、Previously treated with any genetic therapy; 7、The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal; 8、Serum creatinine > 2.5mg/dl or ALT / AST > 3 times ULN or bilirubin > 2.0mg/dl; 9、Those who suffer from other uncontrolled diseases are not suitable to join the study; 10、HIV infection; 11、Any situation that the researchers believe may increase the risk of patients or interfere with the test results.